Human study · Supplements / medicine · 8 Sept 2026
Hormone therapy use for hot flashes and night sweats in menopausal women linked to lower cardiovascular risk
Source: Medical Xpress
What the research found
Study (observational). Virginia Commonwealth University and University of Pittsburgh researchers, using 20 years of SWAN data on women with vasomotor symptoms, report that hormone therapy started in peri- or early postmenopause was linked to about 22% fewer cardiovascular events versus no therapy. Initiation within 10 years of menopause onset was associated with about 27% lower risk; among Black women the estimate was about 49%. No clear reduction was seen when therapy started more than 10 years after menopause. Association is not a prescription. Hormone therapy is clinician-only. Not medical advice and not a substitute for other heart-risk care.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34